AIDS InfoNet Logo
This website is certified by Health On the Net Foundation. Click to verify.
This site complies with the HONcode standard for trustworthy health information:
verify here.

The Henry J. Kaiser Family Foundation
Site of the Week
November 2003

The Health Leader Award 2006
The Health Leader Award 2006

The HOPE Reward Medical Award Featured Site Award

IBS Tales Hope Award Editor's Choice Award

Listed in Listed in Treasures of the Internet

AIDS InfoNet Logo.  The AIDS InfoNet - Reliable, Up-to-Date AIDS Treatment Information
International Association of Providers of AIDS Care
Reviewed June 1, 2016

Fact Sheet 446

Lopinavir + ritonavir (Kaletra)



Lopinavir is a drug used as part of antiretroviral therapy (ART). It is manufactured by Abbvie. Lopinavir is a protease inhibitor. The amount of Lopinavir in the blood stream stays much higher if it is taken with a small amount of ritonavir, another protease inhibitor. See Fact Sheet 442 for more information on ritonavir. Kaletra is a combination of lopinavir and ritonavir in the same tablet. In some countries, Kaletra is sold as Aluvia.  Generic versions have been approved under PEPFAR (see fact sheet 925.)

Protease inhibitors prevent the protease enzyme from working. HIV protease acts like a chemical scissors. It cuts the raw material for HIV into specific pieces needed to build a new virus. Protease inhibitors “gum up” these scissors.



Kaletra was approved in 2000 as an antiretroviral drug (ARV) for people with HIV infection. It has been studied in adults and children. In 2008 it was approved for use in children at least 14 days old.

While antiretroviral therapy (ART) is recommended for all people living with HIV, independent of your symptoms or CD4 count, you and your doctor should consider your CD4 cell count, your viral load, any symptoms you are having, and your attitude about taking ART. Fact Sheet 404 has more information about guidelines for the use of ART.

If you take Kaletra with other ARVs, you can reduce your viral load to extremely low levels, and increase your CD4 cell counts. This should mean staying healthier longer.



Many new copies of HIV are mutations. They are slightly different from the original virus. Some mutations can keep multiplying even when you are taking an ARV. When this happens, the drug will stop working. This is called “developing resistance” to the drug. See Fact Sheet 126 for more information on resistance.

Sometimes, if your virus develops resistance to one drug, it will also have resistance to other ARVs. This is called “cross-resistance”.

Kaletra provides blood levels that are high enough to control HIV that has already developed some resistance to other protease inhibitors.

Resistance can develop quickly. It is very important to take ARVs according to instructions, on schedule, and not to skip or reduce doses.



A film-coated tablet of Kaletra was approved in October 2005. Each tablet contains 200 milligrams (mg) of lopinavir and 50 mg of ritonavir. The normal dose is two tablets twice a day or four tablets once a day (for people whose virus does not have significant resistance to Kaletra or pregnant women).

In November 2007, the FDA approved a formulation for children that contains 100 mg of lopinavir and 25 mg of ritonavir. This version does not require refrigeration.

Kaletra is also available in liquid form. The normal adult dose is 5 milliliters (ml) twice a day. Kaletra tablets can be taken with or without food. Kaletra liquid should be taken with food.

Different doses are used in some combinations. Be sure you know how much Kaletra your doctor has prescribed for you, and when and how to take each dose.

Kaletra is approved for use by children. Their dosage is based on their body weight. Tablets should not be crushed, broken or chewed. This can result in low drug levels.

Kaletra tablets should be kept at room temperature. They are not sensitive to heat. Kaletra liquid can be refrigerated or stored at room temperature for up to 2 months.



The most common side effects of Kaletra are diarrhea, fatigue, headache, and nausea. None of these side effects seem to be very serious. Kaletra can increase the amount of fat (cholesterol and triglycerides) in your blood. High levels of blood fats can increase your risk of problems with your heart or pancreas. The new tablet formulation is expected to cause fewer side effects.



Kaletra is broken down by the liver and can interact with other drugs that also use the liver. Combining these drugs can change the amount of each drug in your bloodstream and cause an under- or overdose. New interactions are constantly being identified. Make sure that your doctor knows about ALL drugs and supplements you are taking.

Drugs to watch out for include other ARVs, drugs to treat tuberculosis (see fact sheet 518), erectile dysfunction (such as Viagra), heart rhythm (antiarrhythmics), and migraine headaches. Interactions are also possible with several antihistamines, sedatives, drugs to lower cholesterol and anti-fungal drugs.

If you are taking liquid Kaletra and ddI, you should take ddI one hour before or two hours after Kaletra. These restrictions do not apply to the new Kaletra tablets.

Take Kaletra one hour apart from antacids.

Kaletra lowers blood levels of methadone. If you are taking methadone you may need to increase the dose. Watch for signs of excessive sedation with buprenorphine.

Some birth control pills may not work if you are taking Kaletra. Talk to your doctor about how to prevent an unwanted pregnancy.

 The herb St. John's Wort (See Fact Sheet 729) lowers the blood levels of some protease inhibitors.

Kaletra lowers blood levels of lamotrigine, a drug used to treat epilepsy and neuropathy. A higher dose of lamotrigine may be required.

Kaletra raises blood levels of midazolam (Versed), a sedative. They should not be taken together without careful monitoring.



Back to Fact Sheet Categories

International Association of Providers of AIDS Care


The AIDS InfoNet is a project of the International Association of Providers of AIDS Care.


United States National Library of Medicine

Partially funded by the National Library of Medicine

Search Our Site
Newest Fact Sheets
Print This Fact Sheet
You can print this fact sheet on a single page in Microsoft Word (.doc) format or Adobe Acrobat (.pdf) format. Click on the links below to open the document in your browser and then print it.
 Adobe Acrobat PDF
 Microsoft Word

You can print directly from your browser using the link below. The printout will probably go onto a second page.
 Print Version (Web)

Monthly E-mail Updates

The InfoNet updates its Fact Sheets frequently. A listing of each month's changes is posted to several e-mail lists.

If you would like to receive this monthly update by personal e-mail, please click on the SUBMIT button.